Topic summary

Retatrutide mass and identity: what a report should show

Compounds › Retatrutide TRIUMPH programme preprint retatrutide effect size Solved

This is a generated summary. It shows the 5 most-liked posts from a topic of 28, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

n.torrenceTL3Regular18 Jun 2026#1

Posting this under the heading it deserves: Retatrutide mass and identity: what a report should show Everything below is what sits behind that.

Comparing SURMOUNT-4 (JAMA, 2024) with STEP 4 (JAMA, 2021) and finding the comparison harder than it looks.

Different populations, different durations, different endpoints defined slightly differently, and in one case a different estimand. People compare the headline percentages anyway, including me until recently.

Is there a defensible way to put these side by side, or is the honest answer that there is not and we should stop?

21 likes 1mo

t.karlsenTL2 Moderator21 Jun 2026#2

Glucagon receptor agonism seems paradoxical in a weight-loss compound because glucagon raises blood glucose. The paradox resolves because glucagon agonism also increases energy expenditure and promotes hepatic fat oxidation, and the incretin components offset the glycaemic effect. In diabetes trials, HbA1c improved rather than worsened.

24 likes 1mo

cannula_notesTL2Member Solution30 Jun 2026#7

Triple agonism: is the effect additive, synergistic, or neither? A phase 2 comparison of tirzepatide (dual) to retatrutide (triple) would answer that question. The published data does not include such a direct comparison.

7 likes 28d

p.mwangiTL2 Moderator9 Jul 2026#13

n.ekstrom, post #3: For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use. Go to post

On post #9 — agreed on the reasoning, with one qualification.

The phase 2 obesity paper reported dose-dependent weight reduction of a magnitude that attracted attention. It also reported dose-dependent heart-rate increases. The heart-rate signal is the reason phase 3 exists rather than something assumed negligible based on phase 2.

28 likes in reply to #3 19d

f.weissTL2 Moderator14 Jul 2026#17

t.karlsen, post #2: Glucagon receptor agonism seems paradoxical in a weight-loss compound because glucagon raises blood glucose. The paradox resolves because glucagon agonism also increases energy expenditure and promotes hepatic fat oxidation, and the incretin components offset the glycaemic effect. In diabetes trials, HbA1c improved rather than worsened. Go to post

Worth separating two things that post #13 runs together.

Retatrutide is investigational. Anything obtained outside a trial is by definition research-use-only material with no human-use authorisation. This site will state that plainly rather than winking at it.

20 likes in reply to #2 14d

Read the full topic (28 posts)

Suggested topics

Topic	Participants	Replies	Views	Activity
Second pass at: Retatrutide dose escalation in the published trials Compounds › Retatrutide retatrutide randomised trial preprint Under review Second pass at: Retatrutide dose escalation in the published trials — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016) cited in support of a claim…	+115	125	30k	2y
Follow-up: Retatrutide phase 2 in type 2 diabetes: the Lancet paper Compounds › Retatrutide retatrutide effect size TRIUMPH programme preprint Retatrutide phase 2 in type 2 diabetes: the Lancet paper Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a claim I…	+1	5	31k	8mo
Retatrutide's phase 2 heart-rate signal and how to think about it — the long version Compounds › Retatrutide effect size randomised trial TRIUMPH programme Solved Retatrutide's phase 2 heart-rate signal and how to think about it — the long version Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J Med…		2	103	17mo
Second pass at: Retatrutide mass and identity: what a report should show Compounds › Retatrutide retatrutide randomised trial effect size Solved Second pass at: Retatrutide mass and identity: what a report should show — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 4 ( JAMA , 2021)…	+65	71	4.6k	13mo
[2026 update] What we do not know about retatrutide, listed explicitly Compounds › Retatrutide TRIUMPH programme preprint effect size randomised trial Wiki What we do not know about retatrutide, listed explicitly — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SCALE ( N Engl J Med , 2015) with STEP 2 ( Lancet ,…	+79	83	952	11mo

Related topics — sharing the tags TRIUMPH programme, preprint, retatrutide

Topic	Participants	Replies	Views	Activity
What would change my mind about repair peptides: a specific answer — one year on Compounds › Repair & healing peptides needs a source observational data TB-500 preprint Closed What would change my mind about repair peptides: a specific answer — one year on I have a specific reason for asking rather than idle curiosity, and the context is below. Session topic: STEP 1 ( N Engl J Med…	+9	13	42k	19mo
Analytical identity of BPC-157: a 15-mer with a simple mass — does this still hold? Compounds › Repair & healing peptides needs a source preprint BPC-157 Analytical identity of BPC-157: a 15-mer with a simple mass — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURPASS-2 ( N Engl J…	+28	33	1.6k	1mo
Journal club: SELECT, absolute risk, and how it was reported Evidence › Journal club journal club estimand randomised trial effect size Journal club: SELECT, absolute risk, and how it was reported Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURMOUNT-OSA ( N Engl J Med , 2024). Please read…		2	52k	1mo
What pooling buys you and what it destroys Evidence › Meta-analyses publication bias risk of bias meta-analysis heterogeneity Solved The question in the title: What pooling buys you and what it destroys I will give what I have already checked below so nobody repeats it. Comparing SURMOUNT-2 ( Lancet , 2023) with LEADER ( N Engl J Med ,…	+74	83	6.6k	8mo
A well-designed study with a badly written abstract Evidence › Study critique disputed effect size risk of bias observational data Posting this under the heading it deserves: A well-designed study with a badly written abstract Everything below is what sits behind that. Comparing SCALE ( N Engl J Med , 2015) with LEADER ( N Engl J Med ,…	+117	128	7.2k	14mo